136 related articles for article (PubMed ID: 34071914)
41. Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor.
Lipiński PFJ; Garnuszek P; Maurin M; Stoll R; Metzler-Nolte N; Wodyński A; Dobrowolski JC; Dudek MK; Orzełowska M; Mikołajczak R
EJNMMI Res; 2018 Apr; 8(1):33. PubMed ID: 29663167
[TBL] [Abstract][Full Text] [Related]
42. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
43. The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y.
Maurin M; Garnuszek P; Baran P; Pawlak D; Mikołajczak R
Nucl Med Rev Cent East Eur; 2015; 18(2):51-5. PubMed ID: 26315862
[TBL] [Abstract][Full Text] [Related]
44. 1,4-Disubstituted 1,2,3-Triazoles as Amide Bond Surrogates for the Stabilisation of Linear Peptides with Biological Activity.
Rečnik LM; Kandioller W; Mindt TL
Molecules; 2020 Aug; 25(16):. PubMed ID: 32781656
[TBL] [Abstract][Full Text] [Related]
45. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
46. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.
Sosabowski JK; Matzow T; Foster JM; Finucane C; Ellison D; Watson SA; Mather SJ
J Nucl Med; 2009 Dec; 50(12):2082-9. PubMed ID: 19910426
[TBL] [Abstract][Full Text] [Related]
47. Design, preparation and biological evaluation of a
Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
[TBL] [Abstract][Full Text] [Related]
48. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
[TBL] [Abstract][Full Text] [Related]
49. One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [
Kanellopoulos P; Kaloudi A; Rouchota M; Loudos G; de Jong M; Krenning EP; Nock BA; Maina T
Pharmaceutics; 2020 Nov; 12(12):. PubMed ID: 33256013
[TBL] [Abstract][Full Text] [Related]
50. In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl.
D'Andrea LD; Testa I; Panico M; Di Stasi R; Caracò C; Tarallo L; Arra C; Barbieri A; Romanelli A; Aloj L
Biopolymers; 2008; 90(5):707-12. PubMed ID: 18615495
[TBL] [Abstract][Full Text] [Related]
51. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.
de Jong M; Bakker WH; Bernard BF; Valkema R; Kwekkeboom DJ; Reubi JC; Srinivasan A; Schmidt M; Krenning EP
J Nucl Med; 1999 Dec; 40(12):2081-7. PubMed ID: 10616889
[TBL] [Abstract][Full Text] [Related]
52. (99m)Tc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice.
Kaloudi A; Nock BA; Lymperis E; Krenning EP; de Jong M; Maina T
Nucl Med Biol; 2016 Jun; 43(6):347-54. PubMed ID: 27260775
[TBL] [Abstract][Full Text] [Related]
53. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
54. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
[TBL] [Abstract][Full Text] [Related]
55. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.
Roosenburg S; Laverman P; Joosten L; Eek A; Oyen WJ; de Jong M; Rutjes FP; van Delft FL; Boerman OC
Bioconjug Chem; 2010 Apr; 21(4):663-70. PubMed ID: 20302291
[TBL] [Abstract][Full Text] [Related]
56. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
57. Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
Felber VB; Valentin MA; Wester HJ
EJNMMI Radiopharm Chem; 2021 Feb; 6(1):10. PubMed ID: 33638060
[TBL] [Abstract][Full Text] [Related]
58. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
59. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
60. Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT).
Grzmil M; Boersema P; Sharma A; Blanc A; Imobersteg S; Pruschy M; Picotti P; Schibli R; Behe M
J Hematol Oncol; 2022 Aug; 15(1):123. PubMed ID: 36045419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
